Cero Therapeutics 8-K Report: Key Stock Insights for February 2025
The provided section of the financial report contains several crucial pieces of information regarding Cero Therapeutics Holdings, Inc. Here are the key insights extracted:
- Entity Identification:
- Company Name: Cero Therapeutics Holdings, Inc.
- SEC Central Index Key (CIK): 0001870404
- Filing Type: 8-K (a current report required by the SEC to report major events that shareholders should know about)
- Filing Date:
- Date of Report: February 12, 2025
- Stock Information:
- Common Stock:
- Par value of $0.0001 per share.
- Ticker symbol: CERO on NASDAQ.
- Warrants:
- Each whole warrant is exercisable for one share of common stock.
- Ticker symbol: CEROW on NASDAQ.
- Financial Context:
- The report references a specific context with dates, indicating that it covers information as of the reporting date (February 12, 2025).
- The financial metrics are measured in USD and shares, suggesting that the report includes data relevant to stock performance and capital structure.
- Reporting Structure:
- The document utilizes XBRL (eXtensible Business Reporting Language) for structured data reporting, which is a standard for electronic communication of business and financial data.
- Contact Information:
- Address: 201 Haskins Way, Suite 230, South San Francisco, CA 94080
- Phone Number: 650-407-2376
Summary of Insights:
Cero Therapeutics Holdings, Inc. reported on February 12, 2025, regarding its common stock and warrants, indicating active trading on NASDAQ. The company has a low par value for its common stock, which is typical for many startups and emerging growth companies. The structured format of the filing suggests compliance with SEC regulations, providing transparency to investors. This report is significant as it may follow key corporate actions or events that could impact the stock's market performance.